AUTHORS
Jorne Migchelbrink, MD, Joost Boerman2, Anno Saris, MD, PhD3, Joost A.A. Scheffers, MD4, Anne M Spanjaart, MD5, Elise RA Pennings, MD, MSc6, Theo Rispens, MD, PhD7, Amaria Vledder8, Jaap A. Van Doesum9, Marjolein van der Poel, MD, PhD10, Yasmina Serroukh11, Pim G.N.J. Mutsaers, MD12, Astrid Pulles13, Margot Jak14, Suzanne Van Dorp15, Tom Van Meerten, MD, PhD16, Joost S.P. Vermaat, MD, PhD, MSc17, Dirk Jan A R Moes, MD, PhD18, Marie Jose Kersten, MD19, Maria Kuipers, MD, PhD20
AFFILIATIONS
1 Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands, Cancer Center Amsterdam, Amsterdam, Netherlands, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, Netherlands
2 Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands
3 Sanquin Research, Amsterdam, Netherlands
4 Leiden University Medical Center, Leiden, Netherlands
5 Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands, Cancer Center Amsterdam, Amsterdam, Netherlands, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, Netherlands
6 Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands, Cancer Center Amsterdam, Amsterdam, Netherlands, Erasmus University Rotterdam, Rotterdam, Netherlands, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, Netherlands
7 Sanquin Research, Amsterdam, Netherlands
8 Clinical Research Unit, Amsterdam, Netherlands
9 University Medical Center Groningen, Groningen, Netherlands
10 Maastricht University Medical Center, Maastricht, Netherlands
11 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
12 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
13 University Medical Center Utrecht, Utrecht, Netherlands
14 University Medical Center Utrecht, Utrecht, Netherlands
15 Radboud University Medical Center, Nijmegen, Netherlands
16 University Medical Center Groningen, Groningen, Netherlands
17 Leiden University Medical Center, Leiden, Netherlands
18 Leiden University Medical Center, Leiden, Netherlands
19 Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands, Cancer Center Amsterdam, Amsterdam, Netherlands, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, Netherlands
20 Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands, Cancer Center Amsterdam, Amsterdam, Netherlands, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, Netherlands
ABSTRACT
Introduction
Cytokine release syndrome (CRS) is the most common adverse event after CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The interleukin-6 (IL-6) receptor antagonist tocilizumab is approved at 8 mg/kg (max. 800 mg, 1-4 doses), but this dosing regimen was extrapolated from rheumatoid arthritis trials and has never been prospectively optimized for CRS.
During the COVID-related tocilizumab shortage, 4 Dutch hospitals continued weight-based dosing (8 mg/kg, 1-4 doses), whereas 3 hospitals adopted fixed dosing (600 mg, with an optional second and final dose of 400 mg). This fixed-dose strategy was based on PK/PD modelling of tocilizumab in COVID-ARDS, which showed less variability in tocilizumab exposure than mg/kg dosing while maintaining IL-6 inhibition (Moes et al. Clin Pharmacokinet 2022).
Aims
To compare C-reactive protein (CRP) dynamics, a biomarker of IL-6 inhibition, and clinical outcomes in patients with CAR T-cell-induced CRS receiving weight-based versus fixed-dose tocilizumab and, in a predefined subset, tocilizumab concentration-time profiles and soluble IL-6 receptor (sIL-6R) pharmacodynamics.
Methods
This population-based cohort study included all adult R/R LBCL patients treated with commercial axicabtagene ciloleucel (axi-cel) in the Netherlands between May 2020 and December 2023 who developed CRS and received tocilizumab per either dosing strategy. Clinical data and blood samples were collected prospectively.
Free tocilizumab and sIL-6R concentrations were measured by validated enzyme-linked immunosorbent assays. Population pharmacokinetics were best described by a one-compartment model with parallel first order and Michaelis-Menten elimination.
A non-linear mixed-effects model with B-spline transformation compared CRP dynamics between regimens, adjusting for CRS grade and cumulative dexamethasone dose.
Results
Of 273 axi-cel patients, 259 (95%) developed CRS; 175 patients received protocol-defined tocilizumab (114 [65%] weight-based; 61 [35%] fixed dosing); 84 patients were excluded (no tocilizumab, n=59; non-protocol dosing, n=25). Baseline characteristics were largely balanced, although the fixed-dose cohort had more patients with ≥3 extranodal sites (33% vs 13%, p<0.01) and the weight-based dose cohort had more primary refractory disease (61% vs 38%, p<0.01). The rate of high-risk CAR-HEMATOTOX scores was similar (48% vs 41%, p=0.48).
Median cumulative tocilizumab dose was higher with weight-based dosing (1222 mg [IQR 674-2058] vs 1000 mg [IQR 600-1000], p<0.01), without differences in cumulative dexamethasone dose. CRP suppression after tocilizumab was comparable between cohorts, with slightly lower CRP levels in the fixed-dose cohort between days 6 and 15 (p<0.05).
In the predefined subset from two centers (fixed-dose, n=30; weight-based, n=26), all fixed-dose patients (30/30) maintained tocilizumab concentrations above the IL-6R saturation threshold (5 μg/mL) for at least 25 days. In comparison, all weight-based patients (26/26) also maintained concentrations above this threshold during the first 25 days, but even 88% (23/26) did so for more than 50 days, with comparable sIL-6R pharmacodynamics.
Cohorts did not differ in CRS grade ≥3 (5% vs 8%, p=0.52), median CRS resolution time (5 vs 5 days, p=0.43), or ICANS grade ≥3 (37% vs 31%, p=0.35). However, the weight-based cohort had significantly higher rates of grade ≥3 late neutrophil immune effector cell-associated hematotoxicity (N-ICAHT) (46% vs 31%, p<0.05) and G-CSF use (67% vs 20%, p<0.01). Among infections, a higher proportion were grade ≥3 in the weight-based cohort, both overall (56% vs 37%, p<0.01) and among bacterial infections specifically (75% vs 56%, p=0.02). In multivariable analysis, weight-based dosing remained associated with a higher risk of late N-ICAHT grade ≥3 (OR 1.98, p=0.07) and grade ≥3 infections (OR 3.2, p=0.02).
Conclusions
In this first real-world comparison of tocilizumab dosing regimens for CRS after CAR T-cell therapy, fixed dosing provided comparable CRP suppression and clinical CRS outcomes, with fewer severe N-ICAHT events and infections. Weight-based dosing unnecessarily maintained therapeutic tocilizumab concentrations for up to 50 days, which may increase neutropenia risk. Hospitals could consider implementing fixed dosing of tocilizumab as a strategy to tailor CRS management, reducing costs and contributing to safer CAR T-cell care.
DISCLOSURES
Jorne Migchelbrink, MD: No relevant conflicts of interest to declare.